VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Green tea may provide breast cancer protection

Green tea is high in the antioxidant EGCG (epigallocatechin-3- gallate) which helps prevent the body's cells from becoming damaged and prematurely aged.

8 Apr 2008

Synthetic molecules may be less expensive alternative to therapeutic antibodies

Researchers at UT Southwestern Medical Center have developed a simple and inexpensive method to screen small synthetic molecules and pull out a handful that might treat cancer and other diseases less expensively than current methods.

7 Apr 2008

What change does prokineticin 2/Bv8 have in human hepatocellular carcinoma?

Liver hepatocarcinoma is a highly vascularized cancer, and more and more research is focused on the molecules controlling angiogenesis.

19 Mar 2008

Study shows Parkinson's disease drug dopamine might work in cancer patients

A study published in the March 13 online issue of The Journal of Clinical Investigation shows that dopamine, a drug currently used to treat Parkinson's disease and other illnesses, also might work in cancer patients.

14 Mar 2008

Study aims to improve treatment for children born with heart defects

Trying to understand and stop the collateral lung damage that can occur in babies with congenital heart disease is the focus of a new study.

11 Mar 2008

Glioblastoma multiforme responds to new treatment

One of the toughest cancers to treat effectively is glioblastoma multiforme (GBM), the most common form of primary brain cancer.

28 Feb 2008

ImClone Systems enrols first patient in clinical trial of IMC-1121B to treat liver cancer

ImClone Systems Incorporated has announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer).

26 Feb 2008

New way to grow blood vessels

Researchers at Dana-Farber Cancer Institute have found a previously unknown molecular pathway in mice that spurs the growth of new blood vessels when body parts are jeopardized by poor circulation.

21 Feb 2008

Researchers explain why Avastin can cause potentially fatal brain inflammation

New research by scientists at Schepens Eye Research Institute may help explain why the anti-cancer drug Avastin, which targets a growth factor responsible for creation of new blood vessels, causes potentially fatal brain inflammation in certain patients.

14 Feb 2008

Avastin (bevacizumab) damages brain vessels

The cancer drug Avastin (bevacizumab) is used to treat advanced bowel cancer in combination with chemotherapy.

12 Feb 2008

VEGF-B helps nerve cells cheat death without unwanted side effects

The prototypical member of the VEGF family of proteins, VEGF, has recently been shown to protect cells in the nervous system from death and degeneration.

8 Feb 2008

Lymphangioleiomyomatosis - potential clues into the treatment and diagnosis

Studies published in the Jan. 10 edition of the New England Journal of Medicine (NEJM) are providing clues into the treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive and deadly lung disease that affects women in their childbearing years.

11 Jan 2008

Bevacizumab found to improve survival for patients with advanced breast cancer

Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an anti-angiogenic therapy.

28 Dec 2007

Avastin shows promise for brain cancer

A clinical study conducted at Henry Ford Hospital on the use of a drug to extend the survival of patients with the most common and aggressive type of brain cancer, has yielded results that were significantly better than expected.

17 Dec 2007

Drug study for brain cancer shows promising results

14 Dec 2007

Depression nearly triples the risk of death following a heart attack

...even when accounting for other heart attack risk factors, according to research presented at the American College of Neuropsychopharmacology (ACNP) annual meeting, which showed that among 360 depressed, post myocardial infarction patients followed for more than six years, those who did not recover from their depression in the first six months were more than twice as likely to die.

10 Dec 2007

Lymphatic vessel and lymph node function are restored with growth factor treatment

The frequent spread of certain cancers to lymph nodes often necessitates surgery or radiation therapy that damages the lymphatic system and can cause lymphedema, a condition of localized fluid retention that often increases susceptibility to infections.

4 Dec 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007

How can we know early who will benefit from tumor target therapy?

The precise tailoring of tumor target treatment for patients with cancer is an unmet challenge.

21 Nov 2007

Hormone norepinephrine may hasten the progression of certain blood cancers

Researchers here have shown that in cell cultures, the stress hormone norepinephrine appears to promote the biochemical signals that stimulate certain tumor cells to grow and spread.

20 Nov 2007